Fingolimod (FYT720), a sphingolipid analog drug for MS, has been found to directly bind and inhibit sI2PP2A/SET oncogene, leading to activation of PP2A, a tumor suppressor enzyme, which further upregulates RIPK1-dependent necroptosis to constrain cell growth in A549 human lung cancer cells and in SCID mice implanted with A549/sh-I2PP2A/SET xenografts [280,281]. This evidence concerns the gene RIPK1 and lung carcinoma.